Investors

Press Releases

Propanc Successfully Completes 28-Day Repeat-Dose Toxicity Study for PRP

Apr 27, 2017

Propanc CEO James Nathanielsz's FDA Policy Proposals Published in Pharma Trade Media

Apr 20, 2017

Propanc Provides Update on Reverse Stock Split and Upcoming Milestones & Events

Apr 13, 2017

Propanc Health Group Corporation Presentation Now Available for On-Demand Viewing

Apr 11, 2017

Propanc Health Group Corporation to Webcast, Live, at VirtualInvestorConferences.com April 6

Apr 3, 2017

Propanc Authorizes Reverse Stock Split and Corporate Name Change to Propanc Biopharma, Inc.

Mar 31, 2017

Propanc Receives Patentability Opinion for Method of Treating Cancer Stem Cells

Mar 28, 2017

Propanc Successfully Completes Low Dose Group for GLP-Compliant 28-Day Repeat-Dose Toxicity Study

Feb 14, 2017

Propanc Provides Progress Update on Additional Patent Applications

Jan 24, 2017

Propanc Receives Allowance of Key Patent Application for Method of Treating Solid Tumors in the US

Jan 11, 2017

« Previous
1
2
3
4
5
6
7
8
9
Next »